IAP
シグナル伝達経路
研究分野
- 阻害剤の選択性比較
- 溶解度
| カタログ番号 | 製品カタログ | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | アルコール | ||
| S7597 | BV-6 | 25 mg/mL | 100 mg/mL | 100 mg/mL |
| S7362 | AZD5582 | 100 mg/mL | -1 mg/mL | -1 mg/mL |
| S7025 | Embelin | <1 mg/mL | 59 mg/mL | 12 mg/mL |
| S7009 | LCL161 | <1 mg/mL | 100 mg/mL | 20 mg/mL |
| S7015 | Birinapant | <1 mg/mL | 100 mg/mL | 55 mg/mL |
| S7010 | GDC-0152 | 3 mg/mL | 99 mg/mL | 99 mg/mL |
| S2754 | AT406 (SM-406) | <1 mg/mL | 100 mg/mL | 100 mg/mL |
亜型選択性的な製品
- IAP阻害剤(7)
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S7597 |
BV-6BV-6 is a SMAC mimetic, dual cIAP and XIAP inhibitor. |
IEC-1 cells were transfected with Per1/2 specific siRNAs or a control siRNA. Afterward, the cells were stimulated with TNFa (0.1 ng/ml under basal conditions) in the presence or absence of BV-6 or were left untreated. Activation of caspase-8 (I) and caspases 3/7 (J ) was assayed. Data are presented as the means±SEM of at least 3 independent experiments. *P≤0.05, **P≤0.01. |
|
| S7362 |
AZD5582AZD5582, a novel small-molecule IAP inhibitor, binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP with IC50 values of 15, 21, and 15 |
||
| S7025 |
EmbelinEmbelin, a quinone isolated from the Japanese Ardisia herb, is an inhibitor of X-linked inhibitor of apoptosis (XIAP) with IC50 of 4.1 μM in a cell-free assay. |
(d) Representative plots of apoptosis in Jurkat cells treated with vehicle only, BIO, CN585, Embelin (Emb), BIO plus CN585 or BIO plus CN585 plus Emb.
|
|
| S7009 |
LCL161LCL-161, a small molecule second mitochondrial activator of caspase (SMAC) mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP). |
The Smac mimetic LCL-161, which inhibits cIAP1, modestly sensitizes hair cells to gentamicin damage. (A) Variable LCL-161 concentrations do not affect toxicity to 50 μM neomycin (one-way ANOVA, F4,69 = 1.54, p = 0.199). (B) Variable LCL has a modest but significant effect on gentamicin toxicity (one-way ANOVA, F4,31 = 3.14, p = 0.028), with 10 μM LCL conveying significant sensitization (∗p < 0.05).
|
|
| S7015 |
BirinapantBirinapant is a SMAC mimetic antagonist, mostly to cIAP1 with Kd of <1 nM in a cell-free assay, less potent to XIAP. Phase 2. |
Western blot from tumours harvested at day 5 after treatment showing an increase in PARP cleavage in the irinotecan-treated group.
|
|
| S7010 |
GDC-0152GDC-0152 is a potent antagonist of XIAP-BIR3, ML-IAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Ki of 28 nM, 14 nM, 17 nM and 43 nM in cell-free assays, respectively; less affinity shown to cIAP1-BIR2 and cIAP2-BIR2. Phase 1. |
(a) Apoptosis (SubG0/G1) of DMSO control and GDC-0152-treated cells was determined by flow cytometry of propidium iodide-stained nuclei and percentage of apoptosis is shown. U87MG and GL261 cell lines were treated for 72 h and GBM6 and GBM9 cell lines were treated for 8 days at the indicated concentrations. At these respective time points, percentage of U87MG cells dead by apoptosis, percentage of GL261 cells, percentage of GBM6 cells and percentage of GBM9 cells. Data are expressed as mean+S.E.M. Three independent experiments were performed for the GL261 cell lines and five for the U87MG, GBM6 and GBM9 cell lines. *P<0.05; **P<0.01; ***P<0.005.
|
|
| S2754 |
AT406 (SM-406)AT406 (SM-406) is a potent Smac mimetic and an antagonist of IAP (inhibitor of apoptosis protein via E3 ubiquitin ligase), binding to XIAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, 50- to 100-fold higher affinities than the Smac AVPI peptide. Phase 1. |
G, cells treated with the SM406 (1 μmol/L) for 48 hours were subjected to Western blotting. |
-J-Immunol-20170125.gif)
